Skip to main content
Stuart Orkin, MD, Pediatric Hematology & Oncology, Boston, MA

StuartH.OrkinMD

Pediatric Hematology & Oncology • Boston, MA

David G. Nathan Professor of Pediatrics, Dana-Farber Cancer Institute

Join to view full profile

Dr. Orkin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Orkin's full profile

Already have an account?

  • Office

    1 Blackfan Circle
    Karp Researcg Bldg
    Boston, MA 02115
    Phone+1 617-919-2042
    Fax+1 617-730-0222

Education & Training

  • Boston Children’s Hospital/Boston Medical Center
    Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1976 - 1978
  • Boston Children’s Hospital/Boston Medical Center
    Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1975 - 1976
  • Childrens Hospital
    Childrens HospitalInternship, Transitional Year, 1972 - 1973
  • Harvard Medical School
    Harvard Medical SchoolClass of 1972

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1978 - 2025
  • Pediatrics
    American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

  • Elected Member Institute of Medicine, 1992
  • Elected Member The American Society for Clinical Investigation, 1982
  • Investigator Howard Hughes Medical Institute

Publications & Presentations

PubMed

Abstracts/Posters

  • Core Transcriptional Regulatory Circuitries in AML
    Stuart H. Orkin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

  • Creating the World’s First CRISPR Medicine, for Sickle Cell Disease
    Creating the World’s First CRISPR Medicine, for Sickle Cell DiseaseFebruary 20th, 2025
  • Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem Meetings
    Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem MeetingsFebruary 12th, 2025
  • HMN 2024: How Could a Pill Replace Gene Therapy for Sickle Cell Disease?
    HMN 2024: How Could a Pill Replace Gene Therapy for Sickle Cell Disease?December 20th, 2024
  • Join now to see all

Grant Support

  • Gfi-Proteins In Hematopoietic DevelopmentNational Heart, Lung, And Blood Institute2004–2012
  • Molecular Analysis Of Normal And Thalassemic DNANational Heart, Lung, And Blood Institute1989–2012
  • Hemoglobin Switching: Genetics To TranslationNational Heart, Lung, And Blood Institute2011
  • Human Pluripotent Stem Cell And Progenitor Models Of Cardiac And Blood DiseasesNational Heart, Lung, And Blood Institute2009–2011
  • Research Training In Pediatric OncologyNational Cancer Institute2009–2011
  • Exploiting Mouse Models Of Pediatric Cancers And Epigenetics For TherapyNational Cancer Institute2009–2011
  • Developmental Biology Of Human ErythropoiesisNational Heart, Lung, And Blood Institute2006–2011
  • A Center Of Molecular Developmental HematopoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2011
  • Extending GWAS At The BCL11A Locus To Novel Therapeutics For Hbf InductionNational Heart, Lung, And Blood Institute2009–2010
  • Genetic Approaches To Hemoglobin SwitchingNational Heart, Lung, And Blood Institute2006–2010
  • Modeling Childhood TEL-AML1 (RUNX1)National Cancer Institute2006–2010
  • Center Of Molecular Developmental HematopoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2008
  • Systems Analysis Of Cancer Pathways In Mouse ModelsNational Cancer Institute2005–2008
  • Administrative CoreNational Institute Of Diabetes And Digestive And Kidney Diseases2007
  • Administrative Core And Enrichment ProgramNational Institute Of Diabetes And Digestive And Kidney Diseases2005
  • Molecular Mechanisms Of Tissue Stem Cell PlasticityNational Heart, Lung, And Blood Institute2001–2004
  • Hematopoiesis In NF E2 Gene Targeted ES CellsNational Heart, Lung, And Blood Institute1999–2003
  • Core--Mouse Embryonic Stem Cell And Gene TargetingNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2002
  • Transcription Factor GATA-1 In Terminal Erythroid DevelopmentNational Heart, Lung, And Blood Institute1996–2002
  • Training Grant In GeneticsNational Institute Of General Medical Sciences1994–2000
  • Role Of Bhlh Protein SCL In Hematopoietic DevelopmentNational Institute Of Diabetes And Digestive And Kidney Diseases1997–1998
  • Core--Embryonic Stem Tissue Culture And Mouse CoreNational Institute Of Diabetes And Digestive And Kidney Diseases1997–1998
  • Center For Molecular Development HematopoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1998
  • Hematopoiesis In NF-E2 Gene-Targeted ES CellsNational Heart, Lung, And Blood Institute1994–1998
  • Structure-Function Analysis Of Specific Human GenesEunice Kennedy Shriver National Institute Of Child Health &Human Development1989–1997
  • Molecular Developmental HematopoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1993
  • GeneticsNational Institute Of General Medical Sciences1989–1993
  • Asip-Children'S Hospital-BostonNational Institute Of Mental Health1992
  • Structure Function Analysis Of Specific Human GenesEunice Kennedy Shriver National Institute Of Child Health &Human Development1988
  • Molecular Analysis Of Normal And Tyhalassemic DNANational Heart, Lung, And Blood Institute1985–1988
  • Gordon Research Conference On Molecular GeneticsNational Institute Of General Medical Sciences1987
  • Structure-Function Analysis Of Specific Human GenesEunice Kennedy Shriver National Institute Of Child Health &Human Development1985–1987

Dr. Stuart Orkin, Dr. Stuart Orkin, MD, Dr. S Orkin, Dr. Stuart H. Orkin